Is Q32 Bio Inc. (NASDAQ:QTTB) a buy in 2026?
Hold. Q32 Bio Inc. is a wait-and-watch at today's price, not a fresh buy.
Bempikibart's alopecia data is the whole story, and the next readout decides whether this is a $5 stock or a $25 one.
Where QTTB is headed
Q32 Bio is a binary event wrapped in a $202M market cap. The asset that matters is bempikibart, an anti-IL-7Rα antibody now running in a Phase 2b for severe alopecia areata after the SIGNAL-AA Part A readout in early 2025 missed the primary endpoint on absolute SALT change but showed enough late-emerging hair regrowth signal to keep the program alive. That ambiguity is exactly why the stock sits where it does. The market is paying for optionality, not conviction. Atopic dermatitis was already deprioritized after a disappointing Phase 2a, so the entire equity story now hinges on whether IL-7 blockade can produce a clean, durable SALT-50 or SALT-75 response with longer dosing.
Read the full Compass Direction on QTTB
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $5.67).
See the full QTTB analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Q32 Bio Inc. (NASDAQ:QTTB) a buy in 2026?
Hold. Q32 Bio Inc. is a wait-and-watch at today's price, not a fresh buy. Bempikibart's alopecia data is the whole story, and the next readout decides whether this is a $5 stock or a $25 one.
What is QTTB's Compass Score?
Q32 Bio Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for QTTB?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the QTTB page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.